Contact this trialFirst, we need to learn more about you.
Androgen Receptor Inhibitor
ZEN003694 + Enzalutamide for Prostate Cancer
Recruiting1 awardPhase 2
Margate, Florida
This trial is testing a new drug, ZEN003694, to see if it is more effective than the current standard of care, enzalutamide, in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior abiraterone. Patients will be randomized to receive either ZEN003694 in combination with enzalutamide or enzalutamide monotherapy. The primary endpoint is radiographic progression-free survival (rPFS) by PCWG3 criteria.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service